EUCTR2012-002024-32-AT进行中（未招募）1 期
Mesapol: The effect of mesalazine on molecular pathways of celladhesion in patients with colon polyps - Mesapol
Medizinische Universität Wien, Universitätsklinik für Innere Medizin 3, Abteilung für Gastroenterologie und Hepatologie0 个研究点目标入组 12 人开始时间: 2012年9月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients of at least 18 years of age that have consented to the study procedures and have signed the informed consent form
- •- Patients who attend the clinic for screening colonoscopy
- •- Patients who have an elevated polyp at least 1 cm in diameter located in the colon
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •- Inability to fully comprehend and/or to perform study procedures in the investigator’s opinion
- •- Participation in any other interventional study within 1 month prior to screening
- •- Complete polypectomy at initial colonoscopy
- •- Known intolerance to 5-ASA (or its derivates) or other salicylates
- •- Intake of 5-ASA (or its derivates), any NSAIDs or COX-2 inhibitors 10 days prior to screening
- •- Concomitant medication with NSAIDs, COX-2 inhibitors, steroids, thiopurines, TNF-a antagonists, methotrexate, calcineurin inhibitors or mycophenolate
- •- Presence of diverticulitis, inflammatory bowel disease or infectious colitis
- •- Familial adenomatous polyposis, Lynch-syndrome or juvenile polyposis syndrome
- •- Pregnancy or lactation
研究者
相似试验
进行中（未招募）
1 期
Mesacol: The effect of mesalazine on molecular pathways ofcell adhesion in ulcerative colitislcerative colitisMedDRA version: 14.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2012-002023-15-ATMedizinische Universität Wien, Universitätsklinik für Innere Medizin 3, Abteilung für Gastroenterologie und Hepatologie12
尚未招募
不适用
The involvement of mesalazine concentration in colonic mucosa of patients with ulcerative colitis under treatment with oral mesalazinelcerative ColitisJPRN-UMIN000011455Department of Gastroenterology and Hepatology, Kyoto University Hospital50
进行中（未招募）
不适用
Evaluation of the role of mesalazine in the treatment of diverticular disease of the colon and irritable colon syndrome: A randomised double blind placebo controlled clinical study - NDIrritable bowel Syndrome Diverticular disease of the colonMedDRA version: 9.1Level: LLTClassification code 10009993MedDRA version: 9.1Level: LLTClassification code 10023004EUCTR2008-004228-22-ITSOFAR SPA
进行中（未招募）
1 期
Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D). - Mesalazine for the treatment of IBS-DDiarrhoea-predominant irritable bowel syndromeMedDRA version: 14.0 Level: LLT Classification code 10060849 Term: Diarrhoea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-018340-14-GBniversity of Nottingham136
进行中（未招募）
1 期
Rectal mesalazine for FAP and MAPFamilial adenomatous polyposis(FAP) and MUTYH-associated polyposis (MAP)MedDRA version: 20.1 Level: PT Classification code 10056981 Term: Adenomatous polyposis coli System Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1 Level: LLT Classification code 10059327 Term: Familial adenomatous polyposis System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003076-13-PTInstituto Português de Oncologia de Lisboa Francisco Gentil15